TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: decrease in oxy‐Hb concentrations in the right prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decrease in ln[LF/(LF+HF)] of HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement in mood state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity for malignant lesion detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suture or needle contamination rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: event recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean difference in TST reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of extracorporeal membrane oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mortality within 120 days
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8+ T cells infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FOXP3+ T cells accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease Progression (DP)
Endpoint domain: Physiological/clinical
Primary endpoint: Disease Progression Burden (DPB)
Endpoint domain: Physiological/clinical
Primary endpoint: change in patient self-management knowledge and behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sTfR concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Carotid intima media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Asymptomatic status at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postpartum anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postpartum pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early postpartum depression rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PVAS score improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxygen consumption at respiratory compensation threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary lignan excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary isoflavonoid excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary equol excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DAS remission at week 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal 25(OH)D concentration at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord blood 25(OH)D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants attaining 25(OH)D >50 nmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to start walking with support or independently
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to football
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: lumbar lordotic curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thoracic kyphosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sacral slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C7 plump line distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bacterial numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total peroxyl radical scavenging capacity (TRAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative sore throat
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinically significant weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of liver edge identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Examiner confidence in test results
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: persistent level of limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Uterine tissue concentrations of moxifloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild CNS toxic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Mean peak ropivacaine venous concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative morphine dosages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale (VAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean LAZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of small-for-gestational-age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of severe acute mountain sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaccine intentions for infants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of treated DCI
Endpoint domain: Mortality/survival
Primary endpoint: Minimal vascular resistance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: BDI-II scores at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Coughing after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial pressure response to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urine output at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to first negative fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatinine increase by postoperative day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean amblyopic eye acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trajectories of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BIC%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student scores on the neurological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of flap edge necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Arthroscopic visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative morphine consumption
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pain scores
Endpoint domain: Adverse events/effects
Primary endpoint: dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPH impact index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPSS-quality of life index improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bromage score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting LDL-C, RLP-C and triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial plasma triglyceride levels (net AUC-TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglyceride-content in lipoprotein fractions after fat load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in depression severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebrovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatic events
Endpoint domain: Adverse events/effects
Primary endpoint: Post-prandial glycaemic excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative risk for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: over-involved/protective parenting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of stage 2 or greater pressure ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recording frequency of drug prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of colonies of micro-organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Motor block level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: dysphagia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cancer Disease Specific Survival (CDS)
Endpoint domain: Mortality/survival
Primary endpoint: Intimate Partner Violence (IPV) risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SF-36 physical component
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SF-36 mental component
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical crown height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Papilla height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma interleukin 6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiovascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: judging the severity of clinical episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture free percentage after three years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental satisfaction rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle tone reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90% antiretroviral adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median nerve latency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vomiting/retching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disruption of activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient preference for topical antibiotics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall satisfaction with medication
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse events related to medication
Endpoint domain: Adverse events/effects
Primary endpoint: activity limitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction and confidence in care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Global PSQI score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduction in weekly estazolam consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfactory uterine tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum total cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL:HDL ratio decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of needlestick injury
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall success ratios of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ease of putting on/taking off
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean area under the plasma concentration‐time curve (AUC(∞)) of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent total body clearance of oxycodone (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression profiles of PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: limitation in function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: blood thrombogenicity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Development of diabetes (NIDDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptom scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time to complete suturing task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: days of work participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: reduction in neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client Initiative
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient satisfaction with psychosocial support intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: high-sensitivity C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: high-sensitivity tumor necrosis factor-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: interleukin-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: biochemically confirmed smoking cessation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brachial FMD values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: high‐sensitive C‐reactive protein (hs‐CRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerability and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sympathetic skin response latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sympathetic skin response amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 24-hr high-frequency value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Patient preference for milk over VoLumen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratings of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vaccine efficacy against persistent infection and/or CIN 2/3 due to HPV‐31 variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: reduction in oscillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of naloxone reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reported helmet use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of BDDrFVIII infusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of intravenous access by traditional methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of hydronidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to maximum plasma concentration (t max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macular oedema prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dentin microhardness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: School-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anti-Xa and anti-IIa activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hematoma at the injection site
Endpoint domain: Adverse events/effects
Primary endpoint: combined behavior change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staff prescription adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mesalazine release properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: small intestinal transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: colon arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 7-day PP abstinence at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bed occupancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nurse-to-patient ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total emergency medical care use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: serum albumin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in intraprostatic DHT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: increase in apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in mean benign epithelial cell width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of oseltamivir-zanamivir combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in seizure frequency
Endpoint domain: Adverse events/effects
Primary endpoint: DeltaWMSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CK and CK-MB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ROSC (Return of Spontaneous Circulation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endoscopic cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of esophageal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of hyperthyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urgent revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Loading response of lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: LDL cholesterol goal achievement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum concentrations of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in health-related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global index of patients' experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status